These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 18689864

  • 1. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
    Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Bamias A.
    Ann Oncol; 2009 Jan; 20(1):117-20. PubMed ID: 18689864
    [Abstract] [Full Text] [Related]

  • 2. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.
    Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E.
    Ann Oncol; 2009 Jan; 20(1):137-45. PubMed ID: 18647964
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid].
    Calvo-Villas JM, Tapia Torres M, Govantes Rodríguez J, Carreter de Granda E, Sicilia Guillén F.
    Med Clin (Barc); 2006 Oct 21; 127(15):576-9. PubMed ID: 17153267
    [Abstract] [Full Text] [Related]

  • 5. Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.
    La Verde N, Bareggi C, Garassino M, Borgonovo K, Sburlati P, Pedretti D, Bianchi C, Perrone S, Mihali D, Cobelli S, Mantica C, Rizzo A, Farina G.
    Support Care Cancer; 2008 Nov 21; 16(11):1311-5. PubMed ID: 18663482
    [Abstract] [Full Text] [Related]

  • 6. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
    Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A.
    Haematologica; 2006 Jul 21; 91(7):968-71. PubMed ID: 16757414
    [Abstract] [Full Text] [Related]

  • 7. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
    Cetiner S, Sucak GT, Kahraman SA, Aki SZ, Kocakahyaoglu B, Gultekin SE, Cetiner M, Haznedar R.
    J Bone Miner Metab; 2009 Jul 21; 27(4):435-43. PubMed ID: 19240969
    [Abstract] [Full Text] [Related]

  • 8. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.
    Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, Bucci-Rechtweg C, Su G.
    J Am Dent Assoc; 2010 Nov 21; 141(11):1365-70. PubMed ID: 21037195
    [Abstract] [Full Text] [Related]

  • 9. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
    Grbic JT, Landesberg R, Lin SQ, Mesenbrink P, Reid IR, Leung PC, Casas N, Recknor CP, Hua Y, Delmas PD, Eriksen EF, Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial Research Group.
    J Am Dent Assoc; 2008 Jan 21; 139(1):32-40. PubMed ID: 18167382
    [Abstract] [Full Text] [Related]

  • 10. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid.
    Cafro AM, Barbarano L, Nosari AM, D'Avanzo G, Nichelatti M, Bibas M, Gaglioti D, Taroni A, Riva F, Morra E, Andriani A.
    Clin Lymphoma Myeloma; 2008 Apr 21; 8(2):111-6. PubMed ID: 18501105
    [Abstract] [Full Text] [Related]

  • 11. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients.
    Pozzi S, Marcheselli R, Sacchi S, Baldini L, Angrilli F, Pennese E, Quarta G, Stelitano C, Caparotti G, Luminari S, Musto P, Natale D, Broglia C, Cuoghi A, Dini D, Di Tonno P, Leonardi G, Pianezze G, Pitini V, Polimeno G, Ponchio L, Masini L, Musso M, Spriano M, Pollastri G, Gruppo Italiano Studio Linfomi.
    Leuk Lymphoma; 2007 Jan 21; 48(1):56-64. PubMed ID: 17325848
    [Abstract] [Full Text] [Related]

  • 12. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
    Jackson GH, Morgan GJ, Davies FE, Wu P, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Boyd KD, Osborne WL, Cook G, Child JA.
    Br J Haematol; 2014 Jul 21; 166(1):109-17. PubMed ID: 24673708
    [Abstract] [Full Text] [Related]

  • 13. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
    Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K.
    J Clin Oncol; 2009 Nov 10; 27(32):5356-62. PubMed ID: 19805682
    [Abstract] [Full Text] [Related]

  • 14. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
    Murad OM, Arora S, Farag AF, Guber HA.
    Endocr Pract; 2007 Nov 10; 13(3):232-8. PubMed ID: 17599853
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw.
    Haidar A, Jønler M, Folkmar TB, Lund L.
    Scand J Urol Nephrol; 2009 Nov 10; 43(6):442-4. PubMed ID: 19903091
    [Abstract] [Full Text] [Related]

  • 17. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
    Tosi P, Zamagni E, Cangini D, Tacchetti P, Di Raimondo F, Catalano L, D'Arco A, Ronconi S, Cellini C, Offidani M, Perrone G, Ceccolini M, Brioli A, Tura S, Baccarani M, Cavo M.
    Blood; 2006 Dec 01; 108(12):3951-2. PubMed ID: 17114572
    [No Abstract] [Full Text] [Related]

  • 18. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates.
    Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, Farina L, Piva S, Palumbo A, Boccadoro M, Corradini P.
    Leuk Lymphoma; 2008 Nov 01; 49(11):2156-62. PubMed ID: 19021059
    [Abstract] [Full Text] [Related]

  • 19. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
    Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ.
    J Oral Maxillofac Surg; 2007 Jul 01; 65(7):1328-31. PubMed ID: 17577497
    [Abstract] [Full Text] [Related]

  • 20. Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
    Gabbert TI, Hoffmeister B, Felsenberg D.
    J Cancer Res Clin Oncol; 2015 Apr 01; 141(4):749-58. PubMed ID: 25319961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.